Autres langues Sight Sciences, Inc.

Actions

SGHT

US82657M1053

Temps réel estimé Cboe BZX Autres places de cotation 21:17:49 26/06/2024			Varia. 5j.	Varia. 1 janv.
6,31 ^USD	+3,70%		-1,49%	+21,41%

28/05	Sight Sciences, Inc. annonce la publication d'une nouvelle analyse de l'étude ROMEO montrant des réductions significatives de la pression et des médicaments obtenues avec Omni® ? dans les cas de glaucome léger, modéré et avancé	CI
14/05	Transcript : Sight Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:15 AM

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Sight Sciences Announces the Release of its First Sustainability Report	10/06
Sight Sciences Announces Publication of a New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI across Mild, Moderate, and Advanced Glaucoma	29/05
Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis	28/05
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis	28/05
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma	28/05
Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma	28/05
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference	07/05
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed	03/05
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, vs. Street Est of $18.4M	02/05
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance	02/05
Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024	02/05
Sight Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Sector Update: Health Care Stocks Edge Higher Late Afternoon	29/04
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	29/04
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump	29/04
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump	29/04
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery	29/04
Sight Sciences : SGHT Proxy - Apr'24	26/04
Sight Sciences to Report First Quarter Financial Results on May 2, 2024	18/04
GNW-Adhoc: Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der Senkung des Augeninnendrucks als auch bei der Einnahme von Medikamenten zur Senkung des Augeninnendrucks über einen Zeitraum von 2 Jahren bei Patienten mit Glaukom bekannt	12/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Sight Sciences, Inc.

Actions

SGHT

US82657M1053

Autres langues

Filtres